Therapeutic apheresis


These specialist services remove harmful, disease-forming proteins, chemicals, or cells from patients’ blood

Life-saving patient care

Therapeutic Apheresis is one of our flagship services, and the only one that deals with patients directly. We treat approximately 1,600 adults and children every year from 10 dedicated therapeutic units across the country.

The information on these pages is primarily for Therapeutic Apheresis patients, donors, carers and visitors.

If you are a clinician, you may find the following links useful:

TAS Connect

We are proud to announce that we are improving the process for clinicians referring patients to the Therapeutic Apheresis Service (TAS) by introducing a new platform, TAS Connect, this Winter.

TAS Connect will improve the patient experience by simplifying the referral process for clinicians, through the online portal. It will also support better outcomes for patients by introducing additional safeguards and clinical prompts to ensure referrals are accurate.

TAS Connect will be rolled out in stages, the first of which will focus on plasma exchange referrals. This approach will allow us to review and refine the system with feedback from patients and clinicians before moving to the next stage.

Therapeutic Apheresis Services Feedback Survey

If you are a patient, donor, carer or visitor we would like to hear your feedback on our service

Give your feedback

You're in safe hands

  • Our facilities are regulated by the Care Quality Commission, Human Tissue Authority and the Joint Accreditation Committee - ISCT (Europe) & EBMT (JACIE)
  • We have a longstanding exemplary regulatory performance history
  • Each of our units are co-located in NHS Trust environments to provide continuity of care and access to clinical support services


You may also be interested in